-
The TB Alliance and its partners have completed patient enrollment in REMox
TB, a global Phase III clinical trial, which may result in the registration of
the first new drug approved for the treatment of drug-sensitive TB in nearly 50
years. REMox TB was designed to test whether a moxifloxacin-containing treatment
regimen of just four months can cure drug-sensitive TB patients at rates that
are non-inferior to those achieved with the standard six-month TB regimen. In
total, more than 1,900 patients were enrolled in REMox TB.
02 February 2012 | TB Alliance
-
Expert panels that put together the Department of Health and Human Services antiretroviral therapy (ART) guidelines have advised that the shorter and simpler combination regimen for latent tuberculosis (TB) recently recommended by the Centers for Disease Control and Prevention (CDC) is not suitable for people being treated for HIV.
22 December 2011 | HIVandHepatitis.com
-
The Critical Path to TB Drug Regimens (CPTR) today announced an innovative
agreement between AstraZeneca, Bayer, Sanofi, Tibotec, TB Alliance, and the
World Health Organization to share information on tuberculosis (TB) compounds
within their respective drug pipelines to quickly identify and work together to
develop the most promising TB drug regimen, regardless of sponsor.
10 November 2011 | Critical Path to TB Drug Regimens
-
Access to treatment for drug-resistant tuberculosis (DR-TB) remains compromised, especially in developing countries, because too few pharmaceutical companies manufacture quality-assured drugs. Lack of competition has led to skyrocketing prices and this means that public health budgets are quickly spent.
20 June 2011 | Inter Press Service
-
Justina Banda, 44,says that because she is HIV-positive, it makes her extra prone to tuberculosis, TB. She has had TB three times, most recently last year.
02 June 2011 | Global Press Institute
-
Scientists have identified a key enzyme responsible for destroying lung tissue
in tuberculosis (TB) and say the finding could lead swiftly to new treatments
for the highly infectious disease.
25 April 2011 | Reuters
-
In patients with newly diagnosed tuberculosis, use of a combined 4-drug fixed-dose regimen was found to have comparable outcomes to drugs administered separately, according to a study in the April 13 issue of JAMA, a theme issue on infectious disease and immunology.
12 April 2011 | Eurekalert Medicine & Health
-
Health officials in Ethiopia's capital, Addis Ababa, are concerned about the spread of tuberculosis in the city's crowded public transport networks and tightly packed "DSTV [satellite television] houses" where ardent fans come to watch English and Spanish football.
23 March 2011 | IRIN Plus News
-
Kevin M. DeCock, MD, director of the Center for Global Health at the Centers for Disease Control and Prevention (CDC), speaks with Science Speaks about the fight against TB.
16 March 2011 | Science Speaks: HIV & TB News
-
The standard approach to re-treating tuberculosis (TB) in low and middle
income settings is failing, according to research funded by the
Wellcome Trust. In a study published March 15 in the open access journal
PLoS Medicine, researchers call for improved access to rapid
diagnostics for drug resistant TB, second-line TB treatment and
antiretroviral HIV therapy.
16 March 2011 | Science Daily
Talking points: a checklist for you and your doctorTalking points is designed to help you talk to your doctor about HIV
treatment.
Preventing HIVAn essential resource providing evidence-based information on preventing HIV infection. 
HIV treatment update – Winter 201206 February 2012The new edition of HIV treatment update (HTU) is now...
A visit from Wandsworth Oasis26 January 2012On Wednesday this
week, we were delighted to have a visit...
Adventurers with HIV – a photo gallery19 January 2012Back in
November we sent out a
call for adventurous people with...